Yakult Honsha, 4SC to tackle liver cancer in Japanese patients
Japanese firm Yakult Honsha Co. Ltd. completed phase I trials for resminostat – licensed from German firm 4SC AG – in solid tumors, as the partners hope to move forward with the target indication of hepatocellular carcinoma (HCC) in Japan, where liver cancer is one of the largest causes of cancer-related death.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST